Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Ductal Breast Carcinoma In Situ
Estrogen Receptor Positive

Interventions

DRUG: Afimoxifene
OTHER: Laboratory Biomarker Analysis
OTHER: Placebo
OTHER: Placebo
DRUG: Tamoxifen Citrate

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]